Shetty Aditya V, Wong Deborah J
Division of Hematology-Oncology, UCLA Medical Center, 2825 Santa Monica Boulevard suite 200, Santa Monica, Los Angeles, CA 90404, USA.
Division of Hematology-Oncology, UCLA Medical Center, 2825 Santa Monica Boulevard suite 200, Santa Monica, Los Angeles, CA 90404, USA.
Otolaryngol Clin North Am. 2017 Aug;50(4):775-782. doi: 10.1016/j.otc.2017.03.013.
In patients with locally advanced squamous cell cancer of the head and neck, a multimodality treatment approach is recommended. The addition of platinum-based systemic therapy concurrently with radiation has been shown to be superior to radiation alone and is considered standard therapy for locally advanced disease. No study has shown superiority of induction therapy followed by chemoradiotherapy versus chemoradiotherapy alone. In the adjuvant setting only patients with nodal extracapsular extension or positive margins seem to benefit from chemoradiotherapy versus radiotherapy alone. In the recurrent or metastatic setting, systemic treatment with chemotherapy is palliative. A subset of patients treated with PD-1 immunotherapy may achieve durable responses.
对于局部晚期头颈部鳞状细胞癌患者，推荐采用多模式治疗方法。已证明铂类全身治疗与放疗同时进行优于单纯放疗，被认为是局部晚期疾病的标准治疗。尚无研究表明诱导治疗后序贯放化疗优于单纯放化疗。在辅助治疗中，仅伴有淋巴结包膜外侵犯或切缘阳性的患者似乎从放化疗中比单纯放疗获益更多。在复发或转移的情况下，化疗的全身治疗是姑息性的。接受PD - 1免疫治疗的一部分患者可能会获得持久缓解。
